Nirsevimab (Beyfortus): RSV Protection for Infants

• 2025

  Log in to bookmark this resource.

  Log in
• Susannah Franco

---

Access Resources

• LectureEN
• Ask aRCie About This Resource

About

This video describes Nirsevimab, known as Beyfortus, is a long-acting antibody that helps protect infants from RSV. It isn't a vaccine but works similarly by reducing severe RSV cases and hospital visits. It's given to newborns before or during their first RSV season if the mother didn't get an RSV shot while pregnant. High-risk infants may need it in their second season too. Nirsevimab is injected into the thigh and can be given with other vaccines. Dosage depends on weight, with smaller babies getting 50 mg and larger ones 100 mg per dose; high-risk older infants receive 200 mg split into two shots.

---

Tags

Focus Area: Infectious Disease

Audiences: Nurses; Physicians; Public Health Professionals

Emergency Management Stages: Mitigation; Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Bronchopulmonary Dysplasia; Cystic Fibrosis; Heart Defects, Congenital; Infant, Newborn; Respiratory Syncytial Virus Infections; Premature Birth

Institutions: Pharmacy Consult with Dr. Su

---

More like this

Surveillance for Emerging Threats to Pregnant Women and Infants: Data for Action 2018 · Centers for Disease Control and Prevention (CDC) Hurricane Recovery: Communication Issues 2018 · Centers for Disease Control and Prevention (CDC), Substance Abuse and Mental Health Services Administration (SAMHSA) Pediatric Crisis Standards of Care 2024 · Pediatric Pandemic Network (PPN)

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---